Drug antagonism and single-agent dominance result from differences in death kinetics

Abstract

Cancer treatment generally involves drugs used in combinations. Most prior work has focused on identifying and understanding synergistic drug-drug interactions; however, understanding antagonistic interactions remains an important and understudied issue. To enrich for antagonism and reveal common features of these combinations, we screened all pairwise combinations of drugs characterized as activators regulated cell death. This network is strongly enriched for antagonism, particularly a form of antagonism that we call “single agent dominance”. Single agent dominance refers to antagonisms in which a two-drug combination phenocopies one of the two agents. Dominance results from differences in death onset time, with dominant drugs acting earlier than their suppressed counterparts. We explored mechanisms by which parthanatotic agents dominate apoptotic agents, finding dominance in this scenario caused by mutually exclusive and conflicting use of PARP1. Taken together, our study reveals death kinetics as a predictive feature of antagonism, due to inhibitory crosstalk between death pathways.

Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro

“…A previous study demonstrated that synergism/antagonism is predictable based on MoA in oncology screening. 61 Unfortunately, we found limited evidence of MoA-associated synergism/antagonism (up to 10 μM) for SARS-CoV-2 (Fig. 6).…”

ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells

“…E-4007). S63845 (Mc1-1 LF kinetic analysis using a fluorescence plate reader LF kinetics were determined as described previously (14). SYTOX green (Thermo Fisher Scientific, catalog no.…”

“…To more closely investigate subtype-specific differences in responses to EGFR inhibitors, we profiled sensitivities to the EGFR inhibitor erlotinib in a panel of TNBC cell lines. Erlotinib was tested across an eight-point, log 10 drug titration, and drug sensitivity was measured using a SYTOX green-based assay (14). Because these cell lines grow at different rates, we scored drug sensitivity using the normalized growth rate inhibition (GR).…”

“…The GR value reports drug response in terms of the net population growth rate, but for any given GR value, it is unclear to what extent the observed drug response is due to growth arrest, cell death, or both. Thus, we also measured drug-induced lethal fraction (LF) (dead cells divided by total cells), which more specifically reports druginduced cell killing (14,17). Evaluation of LF kinetics revealed significant drug-induced cell death in PC9, but not in any of the TNBCs tested ( Fig.…”

“…To more formally score these drug-drug interactions, we used two wellvalidated conventions, the Chou-Talalay combination index (CI) and deviation from Bliss independence (DBI) (45,47). CI scores drugdrug interactions relative to a dose additivity reference model, whereas DBI scores interactions relative to a response independence reference model (14,46). These measures of drug-drug interaction can both be used to identify synergistic or antagonistic drug combinations; however, CI and DBI tend to vary due to the differences in how additivity or independence is defined (48).…”